Summary of subject demographic data
. | Control . | SVR* . | HCV-infected† . |
|---|---|---|---|
| Total no. | 58 | 51 | 82 |
| Sex, no. | |||
| Male | 30 | 27 | 40 |
| Female | 28 | 22 | 31 |
| Not reported | 0 | 2 | 11 |
| Race/ethnicity, no. | |||
| White | 41 | 44 | 58 |
| African American | 13 | 1 | 8 |
| Asian | 3 | 1 | 2 |
| Other or not reported | 3 | 5 | 13 |
| Hispanic ethnicity | 6 | 0 | 1 |
| HCV genotype, no. | |||
| Genotype 1a | NA | 8 | 37 |
| Genotype 1b | NA | 5 | 21 |
| Genotype 2 | NA | 7 | 7 |
| Genotype 3 | NA | 0 | 1 |
| Mixed genotypes | NA | 1 | 2 |
| Not available | NA | 30 | 14 |
| Mean age, y (SD) | 35.7 (9.6) | 49.8 (9.5) | 50 (10.4) |
| Duration of SVR, mo (range) | NA | 12.2 (1-72) | NA |
. | Control . | SVR* . | HCV-infected† . |
|---|---|---|---|
| Total no. | 58 | 51 | 82 |
| Sex, no. | |||
| Male | 30 | 27 | 40 |
| Female | 28 | 22 | 31 |
| Not reported | 0 | 2 | 11 |
| Race/ethnicity, no. | |||
| White | 41 | 44 | 58 |
| African American | 13 | 1 | 8 |
| Asian | 3 | 1 | 2 |
| Other or not reported | 3 | 5 | 13 |
| Hispanic ethnicity | 6 | 0 | 1 |
| HCV genotype, no. | |||
| Genotype 1a | NA | 8 | 37 |
| Genotype 1b | NA | 5 | 21 |
| Genotype 2 | NA | 7 | 7 |
| Genotype 3 | NA | 0 | 1 |
| Mixed genotypes | NA | 1 | 2 |
| Not available | NA | 30 | 14 |
| Mean age, y (SD) | 35.7 (9.6) | 49.8 (9.5) | 50 (10.4) |
| Duration of SVR, mo (range) | NA | 12.2 (1-72) | NA |
Patients and control subjects are characterized according to sex, race, and ethnicity (self-reported), HCV genotype if applicable, age, and duration of SVR (time between completion of therapy and collection of sample tested in this report).
NA indicates not applicable.
This group includes the 9 sustained responders from Table 2 who provided a blood sample 6 months after completion of treatment.
This group includes all 29 patients from Table 2.